


10/500895
DT04 Rec'd PCT/PTO 07 JUL 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 0 or 1;

n = 0 or 1;

A is selected from the group consisting of: $-\text{CO}_2\text{H}$, $-\text{PO}_3\text{H}_2$, $-\text{PO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{PO}(\text{C}_1\text{-3alkyl})\text{OH}$ and 1H-tetrazol-5-yl;

R^1 and R^2 are each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-\text{CO}_2\text{H}$ and $\text{C}_1\text{-4alkyl}$, optionally substituted from one up to the maximum number of substitutable positions with halo;

R^3 is selected from the group consisting of: hydrogen and $\text{C}_1\text{-4alkyl}$, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, $\text{C}_1\text{-4alkyl}$ and $\text{C}_1\text{-3alkoxy}$, said $\text{C}_1\text{-4alkyl}$ and $\text{C}_1\text{-3alkoxy}$ optionally substituted from one up to the maximum number of substitutable positions with halo,


C is selected from the group consisting of:

- (1) C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl, said C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl and -CHOH-C₁₋₆alkyl optionally substituted with phenyl, and
- (2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups,

or C is not present;

when C is not present then B is selected from the group consisting of: phenyl, C₅₋₁₆alkyl, C₅₋₁₆alkenyl, C₅₋₁₆alkynyl, -CHOH-C₄₋₁₅alkyl, -CHOH-C₄₋₁₅alkenyl, -CHOH-C₄₋₁₅alkynyl, C₄₋₁₅alkoxy, -O-C₄₋₁₅alkenyl, -O-C₄₋₁₅alkynyl, C₄₋₁₅alkylthio, -S-C₄₋₁₅alkenyl, -S-C₄₋₁₅alkynyl, -CH₂-C₃₋₁₄alkoxy, -CH₂-O-C₃₋₁₄alkenyl, -CH₂-O-C₃₋₁₄alkynyl, -(C=O)-C₄₋₁₅alkyl, -(C=O)-C₄₋₁₅alkenyl, -(C=O)-C₄₋₁₅alkynyl, -(C=O)-O-C₃₋₁₄alkyl, -(C=O)-O-C₃₋₁₄alkenyl, -(C=O)-O-C₃₋₁₄alkynyl, -(C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkyl, -(C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkenyl, -(C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkynyl, -N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkyl, -N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkenyl and -N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkynyl,

when C is phenyl or HET then B is selected from the group consisting of: C₁₋₆alkyl, C₁₋₅alkoxy, -(C=O)-C₁₋₅alkyl, -(C=O)-O-C₁₋₄alkyl, -(C=O)-N(R⁶)(R⁷)-C₁₋₄alkyl, C₁₋₃alkyl



, phenyl and HET, and

when C is C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl then B is phenyl; and

R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁₋₉alkyl and -(CH₂)_p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C₁₋₃alkyl and C₁₋₃alkoxy, each optionally substituted with 1-3 halo groups.

Claim 2 (original): The compound according to Claim 1 wherein:

Ar is phenyl;

the group –**B-C** is attached to the phenyl ring at the 3- or 4-position;

C is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups,


or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: C₇₋₁₂alkyl, C₇₋₁₂alkenyl, C₇₋₁₂alkynyl, C₆₋₁₁alkoxy, -O-C₆₋₁₁alkenyl, -O-C₆₋₁₁alkynyl, -(C=O)-C₆₋₁₁alkyl, -(C=O)-C₆₋₁₁alkenyl, -(C=O)-C₆₋₁₁alkynyl, -(C=O)-O-C₅₋₁₀alkyl, -(C=O)-O-C₅₋₁₀alkenyl, and -(C=O)-O-C₅₋₁₀alkynyl and **C** is not present;

and

when **C** is phenyl or HET then **B** is selected from the group consisting of C₁₋₅alkyl, C₁₋₄alkoxy, -(C=O)-C₁₋₄alkyl, -(C=O)-O-C₁₋₃alkyl, phenyl and HET.

Claim 3 (original): The compound according to Claim 1 wherein HET is selected from the group consisting of:




Claim 7 (original): The compound according to Claim 1 wherein n is 1.

Claim 8 (original): The compound according to Claim 1 wherein **B** is selected from the group consisting of: C₇₋₁₂alkyl, C₇₋₁₂alkenyl, C₇₋₁₂alkynyl, C₆₋₁₁alkoxy, -O-C₆₋₁₁alkenyl, -O-C₆₋₁₁alkynyl, -(C=O)-C₆₋₁₁alkyl, -(C=O)-C₆₋₁₁alkenyl, -(C=O)-C₆₋₁₁alkynyl, -(C=O)-O-C₅₋₁₀alkyl, -(C=O)-O-C₅₋₁₀alkenyl, and -(C=O)-O-C₅₋₁₀alkynyl and **C** is not present.

Claim 9 (original): The compound according to Claim 1 wherein:

B is methoxy and **C** is HET substituted with phenyl and C₁₋₄alkyl, said C₁₋₄alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups.

Claim 10 (original): The compound according to Claim 8 wherein C is selected from the group consisting of:




Claim 11 (original): The compound according to Claim 9 wherein C is thiophene or furan.

Claim 12 (original): The compound according to Claim 1 wherein:

B is methoxy and **C** is HET.

Claim 13 (original): The compound according to Claim 12 wherein **C** is selected from the group consisting of:



Claim 14 (original): The compound according to Claim 13 wherein **C** is benzothiophene or benzofuran.

Claim 15 (original): The compound according to Claim 1 wherein:


B is methoxy and **C** is phenyl substituted with two C_{1-4} alkyl groups, said C_{1-4} alkyl optionally substituted from one up to the maximum number of substitutable positions with halo.

Claim 16 (original): The compound according to Claim 1 wherein:

B is HET and **C** is HET substituted with phenyl and C_{1-4} alkyl, said C_{1-4} alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo, C_{1-4} alkyl, optionally substituted with 1-3 halo groups.

Claim 17 (original): The compound according to Claim 16 wherein **B** is 1,2,4-oxadiazole.

Claim 18 (original): The compound according to Claim 17 wherein **C** is selected from the group consisting of:




Claim 19 (original): The compound according to Claim 18 wherein **C** is thiophene or furan.


Claim 20 (original): The compound according to Claim 1 wherein $m = 0$ and **A** is $-\text{CO}_2\text{H}$.


Claim 21 (original): The compound according to Claim 20 wherein R^1 , R^2 and R^3 are hydrogen.


Claim 22 (original): The compound according to Claim 2 wherein the group **-B-C** is attached to the phenyl ring at the 4-position.









Claim 23 (original): The compound according to Claim 1 selected from the following table:


















Claim 24 (original): A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$n = 0$ or 1 ;

R^3 is selected from the group consisting of: hydrogen and C_{1-4} alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;


each R^4 is independently selected from the group consisting of: halo, C_{1-4} alkyl and C_{1-3} alkoxy, said C_{1-4} alkyl and C_{1-3} alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.








Claim 25 (original): The compound according to Claim 24 wherein n is 0.

Claim 26 (original): The compound according to Claim 24 wherein n is 1.


Claim 27 (original): The compound according to Claim 24 wherein R^3 is hydrogen.

Claim 28 (original): The compound according to Claim 24 selected from the following table:



Claim 29 (original): A compound represented by Formula III



III

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$n = 0$ or 1 ;

R^3 is selected from the group consisting of: hydrogen and C_{1-4} alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;


each R^4 is independently selected from the group consisting of: halo, C_{1-4} alkyl and C_{1-3} alkoxy, said C_{1-4} alkyl and C_{1-3} alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

Claim 30 (original): The compound according to Claim 29 wherein n is 0 .

Claim 31 (original): The compound according to Claim 29 wherein n is 1 .

Claim 32 (original): The compound according to Claim 29 wherein R^3 is hydrogen.

Claim 33 (original): The compound according to Claim 29 selected from the following table:



Claim 34 (original): A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

Claims 35- 46 (canceled)

Claim 47 (original): A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.